American Society of Hirudotherapy

Low-Level Antimicrobials in the Medicinal Leech Select for Resistant Pathogens

Genomics study published in mBio (2018)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportAntimicrobial ResistanceSafety & Infection ControlBeka L et al. · mBio, 2018

Abstract

Fluoroquinolones (FQs) and ciprofloxacin (Cp) are important antimicrobials that pollute the environment in trace amounts. Although Cp has been recommended as prophylaxis for patients undergoing leech therapy to prevent infections by the leech gut symbiont Aeromonas, a puzzling rise in Cp-resistant (Cpr) Aeromonas infections has been reported. We report on the effects of subtherapeutic FQ concentrations on bacteria in an environmental reservoir, the medicinal leech, and describe the presence of multiple antibiotic resistance mutations and a gain-of-function resistance gene. We link the rise of CprAeromonas isolates to exposure of the leech microbiota to very low levels of Cp (0.01 to 0.04 µg/ml), <1/100 of the clinical resistance breakpoint for Aeromonas Using competition experiments and comparative genomics of 37 strains, we determined the mechanisms of resistance in clinical and leech-derived Aeromonas isolates, traced their origin, and determined that the presence of merely 0.01 µg/ml Cp provides a strong competitive advantage for Cpr strains. Deep-sequencing the Cpr-conferring region of gyrA enabled tracing of the mutation-harboring Aeromonas population in archived gut samples, and an increase in the frequency of the Cpr-conferring mutation in 2011 coincides with the initial reports of CprAeromonas infections in patients receiving leech therapy.IMPORTANCE The role of subtherapeutic antimicrobial contamination in selecting for resistant strains has received increasing attention and is an important clinical matter. This study describes the relationship of resistant bacteria from the medicinal leech, Hirudo verbana, with patient infections following leech therapy. While our results highlight the need for alternative antibiotic therapies, the rise of Cpr bacteria demonstrates the importance of restricting the exposure of animals to antibiotics approved for veterinary use. The shift to a more resistant community and the dispersion of Cpr-conferring mechanisms via mobile elements occurred in a natural setting due to the presence of very low levels of fluoroquinolones, revealing the challenges of controlling the spread of antibiotic-resistant bacteria and highlighting the importance of a holistic approach in the management of antibiotic use.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov't
Indexed MeSH termsAeromonasAnimalsAnti-Bacterial AgentsCiprofloxacinDNA GyraseDisease ReservoirsDrug Resistance, Multiple, BacterialFluoroquinolonesGastrointestinal MicrobiomeGram-Negative Bacterial InfectionsHirudo medicinalisHumans

Summary

Demonstrates that subtherapeutic ciprofloxacin in medicinal leech environment selects for resistant Aeromonas strains that subsequently caused patient infections.

Why This Matters for Hirudotherapy

Using competition experiments and comparative genomics of 37 strains, this study links the reported rise of ciprofloxacin-resistant Aeromonas infections after leech therapy to exposure of the medicinal leech (Hirudo verbana) gut microbiota to very low, subtherapeutic fluoroquinolone levels (0.01-0.04 ug/ml, under 1/100 of the clinical resistance breakpoint), identifying resistance mutations in gyrA and a gain-of-function resistance gene and dating an increase in the resistant population to around 2011. This is highly relevant and cautionary for hirudotherapy: Aeromonas is the principal leech-gut symbiont behind post-leeching infection, and the work argues that trace environmental antibiotic contamination can erode the very ciprofloxacin prophylaxis used to prevent those infections, reinforcing the need for antibiotic stewardship and alternative prophylaxis strategies. It is a mechanistic microbiology and genomics study, not a clinical trial; it does not measure patient infection rates under different prophylaxis regimens, so its clinical implications, while important, remain inferential.

Citation

Low-Level Antimicrobials in the Medicinal Leech Select for Resistant Pathogens That Spread to Patients.

Beka L et al. · mBio, 2018

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.